| ChemoCentryx Reports CCX140-B Meets Primary Endpoint and Demonstrates Clinical ... - MarketWatch (press release) |
|
|
MarketWatch (press release) These combined results indicate that CCX140-B may be effective in the treatment of renal disease resulting from complications associated with diabetes. CCX140-B is in position to enter Phase II clinical development for the treatment of diabetic |